» Articles » PMID: 22818564

A Comparison of Non-HDL and LDL Cholesterol Goal Attainment in a Large, Multinational Patient Population: the Lipid Treatment Assessment Project 2

Overview
Journal Atherosclerosis
Publisher Elsevier
Date 2012 Jul 24
PMID 22818564
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This study evaluated the success in attaining non-HDL-cholesterol (non-HDL-C) goals in the multinational L-TAP 2 study.

Methods: 9955 patients ≥20 years of age with dyslipidemia on stable lipid-lowering therapy were enrolled from nine countries.

Results: Success rates for non-HDL-C goals were 86% in low, 70% in moderate, and 52% in high-risk patients (63% overall). In patients with triglycerides of >200 mg/dL success rates for non-HDL-C goals were 35% vs. 69% in those with ≤200 mg/dL (p < 0.0001). Among patients attaining their LDL-C goal, 18% did not attain their non-HDL-C goal. In those with coronary disease and at least two risk factors, only 34% and 30% attained respectively their non-HDL-C and LDL-C goals. Rates of failure in attaining both LDL-C and non-HDL-C goals were highest in Latin America.

Conclusions: Non-HDL-C goal attainment lagged behind LDL-C goal attainment; this gap was greatest in higher-risk patients.

Citing Articles

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.

Michaeli D, Michaeli J, Albers S, Boch T, Michaeli T Am J Cardiovasc Drugs. 2023; 23(5):477-495.

PMID: 37486464 PMC: 10462544. DOI: 10.1007/s40256-023-00594-5.


Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review.

Bruckert E, Parhofer K, Gonzalez-Juanatey J, Nordestgaard B, Arca M, Giovas P Adv Ther. 2020; 37(5):1724-1736.

PMID: 32200537 PMC: 7467492. DOI: 10.1007/s12325-020-01285-2.


Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies.

Toth P, Jones S, Monsalvo M, Elliott-Davey M, Lopez J, Banach M J Am Heart Assoc. 2020; 9(5):e014129.

PMID: 32114889 PMC: 7335559. DOI: 10.1161/JAHA.119.014129.


Large-Scale Phenome-Wide Association Study of Variants Demonstrates Protection Against Ischemic Stroke.

Rao A, Lindholm D, Rivas M, Knowles J, Montgomery S, Ingelsson E Circ Genom Precis Med. 2018; 11(7):e002162.

PMID: 29997226 PMC: 6050027. DOI: 10.1161/CIRCGEN.118.002162.


Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.

Henry R, Muller-Wieland D, Taub P, Bujas-Bobanovic M, Louie M, Letierce A Diabetes Obes Metab. 2018; 20(7):1632-1641.

PMID: 29493859 PMC: 6033097. DOI: 10.1111/dom.13273.